

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED**

**華康生物醫學控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 8622)**

**VOLUNTARY ANNOUNCEMENT  
IMPACT OF NOVEL CORONAVIRUS (COVID-19) EPIDEMIC ON  
BUSINESS OPERATIONS**

This announcement is made by Huakang Biomedical Holdings Company Limited (the “**Company**”, and together with its subsidiaries, collectively referred to as the “**Group**”) on a voluntary basis.

Since the outbreak of the novel coronavirus (COVID-19) epidemic (the “**Epidemic**”), a number of provinces and municipalities in the People’s Republic of China (“**PRC**”) have taken emergency public health measures and various actions to prevent the spread of the Epidemic, including imposing restriction on the work resumption date after the Chinese New Year Holidays.

The Group’s factory located in Shenzhen (the “**Shenzhen Factory**”) has, after around five weeks’ production halt due to the Chinese New Year Holidays and complying with the local government’s preventive policies, resumed production on 24 February 2020. However, as a result of suspension or limited service of transport in certain regions in the PRC and the fact that a number of our workers are subject to mandatory quarantine by the local government, certain workers are unable to return to the Shenzhen Factory as planned, leading to a temporarily drop in the production capacity of the Shenzhen Factory. It is expected that the Shenzhen Factory will experience delay in resuming their original production schedule and there will be late delivery of products in the coming few months. Nonetheless, it is expected that the shortage of labour as a result of the administrative measures arising from the Epidemic is temporary.

Under such special circumstances, the Group will use its best endeavours to fulfil its committed sales order and liaise with its customers to adjust the delivery schedule to minimise any negative economic impact on both sides.

The board of directors of the Company will continue to assess the impact of the Epidemic on the operation and financial performance of the Group, while closely monitoring the development of the Epidemic and the risks and uncertainties faced by the Group as a result of the Epidemic. The Company will take appropriate measures as necessary and make further announcements as and when appropriate.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Huakang Biomedical Holdings Company Limited**  
**Zhang Shuguang**  
Chairman and Executive Director

Hong Kong, 25 February 2020

*As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the Independent Non-executive Directors are Dr. Yeung David Wai Chow, Mr. Kwok Chi Shing and Mr. Chan Kin Sang.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least seven days from the date of publication and on the Company’s website at [www.huakangbiomedical.com](http://www.huakangbiomedical.com).*